Coherus BioSciences Inc CHRS.OQ CHRS.O is expected to show a fall in quarterly revenue when it reports results on March 10 for the period ending December 31 2024
The Redwood City California-based company is expected to report a 48.4% decrease in revenue to $47.27 million from $91.52 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Coherus BioSciences Inc is for a loss of 13 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Coherus BioSciences Inc is $7.00, above its last closing price of $1.00.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.16 | -0.13 | -0.01 | Beat | 92.5 |
Jun. 30 2024 | -0.29 | -0.29 | -0.14 | Beat | 51.7 |
Mar. 31 2024 | -0.25 | -0.24 | -0.32 | Missed | -32.3 |
Dec. 31 2023 | -0.14 | -0.12 | -0.62 | Missed | -420.3 |
Sep. 30 2023 | -0.29 | -0.27 | -0.27 | Met | 1.7 |
Jun. 30 2023 | -0.48 | -0.48 | -0.38 | Beat | 21.6 |
Mar. 31 2023 | -0.54 | -0.57 | -0.75 | Missed | -31 |
Dec. 31 2022 | -0.87 | -0.84 | -0.60 | Beat | 28.4 |
This summary was machine generated March 7 at 20:30 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。